Advanced search
Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Email Registration
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nyse
  5. AbbVie Inc.
  6. News
  7. Summary
    ABBV   US00287Y1091

ABBVIE INC.

(ABBV)
  Report
Real-time Estimate Cboe BZX  -  01:32:47 2023-01-27 pm EST
146.50 USD   -0.61%
01/25Allergan Aesthetics takes a 360°approach to non-surgical aesthetic treatments to improve patient outcomes with expert-led medical education symposium at IMCAS 2023
PR
01/23Abbvie : St. Jude Children's Research Hospital unveils 45,000-square-foot Family Commons
PU
01/20Netflix changes management, T-Mobile US hacked again: MarketScreener's World Press Review, January 20
MS
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Transcript : AbbVie Inc. Presents at 5th Annual Evercore ISI HealthCONx Conference 2022, Nov-29-2022 10:55 AM

11/29/2022 | 10:55am EST
share with twitter
share with LinkedIn
share with facebook
All right. Welcome, everyone. This is Gavin Clark-Gartner and Josh Schimmer from the Evercore ISI biotech research team, and we're very happy to be here with the AbbVie team. Full house, we have Rob...


© S&P Capital IQ 2022
All news about ABBVIE INC.
01/25Allergan Aesthetics takes a 360°approach to non-surgical aesthetic treatments to improv..
PR
01/23Abbvie : St. Jude Children's Research Hospital unveils 45,000-square-foot Family Commons
PU
01/20Netflix changes management, T-Mobile US hacked agai..
MS
01/19Health Rounds: AI speeds MRI exams
RE
01/19Juvederm volux xc for improvement of jawline definition now available nationwide
AQ
01/18AbbVie's Allergan Aesthetics Launches JUVEDERM VOLUX for Non-Surgical Jawline Augmentat..
MT
01/18JUVÉDERM® VOLUX™ XC FOR IMPROVEMENT OF JAWLINE DEFINITION NOW AVAILABLE NATIONWID..
PR
01/17Global markets live: Ocado, Goldman Sachs, Morgan Stanley, PwC...
MS
01/17Mixed earnings reports weigh on US stocks
MS
01/17Piper Sandler Adjusts Price Target on AbbVie to $157 From $155, Maintains Overweight Ra..
MT
More news
Analyst Recommendations on ABBVIE INC.
More recommendations
Financials (USD)
Sales 2022 58 279 M - -
Net income 2022 14 521 M - -
Net Debt 2022 54 782 M - -
P/E ratio 2022 17,8x
Yield 2022 3,85%
Capitalization 261 B 261 B -
EV / Sales 2022 5,41x
EV / Sales 2023 5,62x
Nbr of Employees 50 000
Free-Float 97,4%
Chart ABBVIE INC.
Duration : Period :
AbbVie Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ABBVIE INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Last Close Price 147,40 $
Average target price 162,32 $
Spread / Average Target 10,1%
EPS Revisions
Managers and Directors
Richard A. Gonzalez Chairman & Chief Executive Officer
Robert A. Michael Vice Chairman & President
Scott T. Reents Chief Financial Officer & Executive Vice President
Thomas J. Hudson VP, Head-Oncology Discovery & Early Development
Azita Saleki-Gerhardt Executive Vice President-Operations
Sector and Competitors
1st jan.Capi. (M$)
ABBVIE INC.-8.79%260 586
JOHNSON & JOHNSON-4.04%441 560
ELI LILLY AND COMPANY-4.40%330 671
NOVO NORDISK A/S0.14%309 711
ROCHE HOLDING AG-0.52%277 411
MERCK & CO., INC.-3.68%270 958